What is the Advanced Medical Device Acceleration Project (AMDAP)?

AMDAP is a project by the Tokyo Metropolitan Government to support the development and commercialization of advanced medical devices by venture companies and SMEs in Tokyo. It provides guidance from experts and financial subsidies for promising business plans.

What is Physiologas's business plan for this project?

Physiologas plans to develop a compact home hemodialysis device that does not require tap water and can be easily operated by patients at home. This is achieved through a technology that recirculates dialysate within the system.

What are the benefits of Physiologas's proposed device?

The device aims to reduce the burden on patients by eliminating the need for hospital visits and simplifying operation compared to current devices. It also eliminates the need for external water supply and drainage facilities.

How much funding will Physiologas receive?

Physiologas has been selected for a subsidy of up to 600 million yen over a maximum of 6 years.

What is the goal of this project for Physiologas?

The goal is to accelerate the social implementation of home hemodialysis to improve the quality of life for patients with end-stage renal failure and their families.

AI News NQ Analysis

Physiologas Selected for Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project (AMDAP)

NQ Score 50/100

AI Summary (NQ-processed)

Physiologas selected for Tokyo AMDAP, accelerating development of home hemodialysis device.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the Advanced Medical Device Acceleration Project (AMDAP)?: A: AMDAP is a project by the Tokyo Metropolitan Government to support the development and commercialization of advanced medical devices by venture companies and SMEs in Tokyo. It provides guidance from experts and financial subsidies for promising business plans.
Q: What is Physiologas's business plan for this project?: A: Physiologas plans to develop a compact home hemodialysis device that does not require tap water and can be easily operated by patients at home. This is achieved through a technology that recirculates dialysate within the system.
Q: What are the benefits of Physiologas's proposed device?: A: The device aims to reduce the burden on patients by eliminating the need for hospital visits and simplifying operation compared to current devices. It also eliminates the need for external water supply and drainage facilities.
Q: How much funding will Physiologas receive?: A: Physiologas has been selected for a subsidy of up to 600 million yen over a maximum of 6 years.
Q: What is the goal of this project for Physiologas?: A: The goal is to accelerate the social implementation of home hemodialysis to improve the quality of life for patients with end-stage renal failure and their families.